Introduction/Background Recommendations for adjuvant radiotherapy for node negative, early-stage CC are generally based on the results from the GOG92 study by Sedlis et al. However, the SEDLIS criteria has been challenged by new insights gained the past decades. Utilizing population-based quality registries, we investigated the association between adjuvant therapy and recurrence-free survival (RFS) in intermediate risk cervical cancer patients.

Methodology Women diagnosed with FIGO 2018 stage IB2-IIA2 cervical cancer between 2005 and 2022 were identified from three nationwide population-based registries: the Danish Gynaecological Cancer Database, the Swedish Quality Registry for Gynaecologic Cancer, and the Netherlands Cancer Registry. Inclusion criteria were common histologies (squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma), treated with radical hysterectomy and pelvic lymphadenectomy.

Results The database comprise approximately 1000 patients fulfilling the inclusion criteria. Oncologic outcomes will be displayed as Kaplan-Meier curves and logistic regression analyses using various combinations of predefined risk factors

Conclusion The results from this study may be used to revise current recommendations for adjuvant therapy in early-stage cervical cancer.

Disclosures Nothing to disclose.